Invention Title:

PSILOCYBIN COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING THE SAME

Publication number:

US20240197758

Publication date:

2024-06-20

Section:

Human necessities

Class:

A61K31/661

Inventors:

David Philip ELDER Hertfordshire, Great Britain (UK)

Nigel RICHARDSON Stevenage, Great Britain (UK)

Assignee:

Compass Pathfinder Limited Altrincham, Cheshire, Great Britain (UK)

Applicant:

Compass Pathfinder Limited Altrincham, Cheshire, Great Britain (UK)

Drawings (4 of 23)

Drawing 01 for PSILOCYBIN COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING THE SAME

Drawing 02 for PSILOCYBIN COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING THE SAME

Drawing 03 for PSILOCYBIN COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING THE SAME

Drawing 04 for PSILOCYBIN COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING THE SAME

Smart overview of the Invention

Pharmaceutical compositions containing psilocybin are designed to provide a therapeutically effective amount alongside one or more acceptable excipients. These formulations aim to treat depressive disorders by ensuring stability and uniformity during storage and use.

Background on Psilocybin

Psilocybin is classified as a psychedelic compound, primarily affecting serotonin receptors. Initially derived from psilocybe mushrooms, it poses unique challenges in formulation due to its physical properties and potential chemical instability. There is a growing demand for stable psilocybin compositions that comply with regulatory standards.

Formulation Challenges

Creating stable solid dosage forms of psilocybin is complex due to its crystalline structure and poor flow properties. Issues such as discoloration and potency loss during stability testing have been observed when using common excipients. Therefore, it is crucial to develop formulations that maintain potency and content uniformity over time.

Pharmaceutical Composition Details

The compositions should ensure that the potency of psilocybin decreases by less than 5% after one month under specific storage conditions. Additionally, the mass balance of psilocybin and related substances must exceed 97%, meeting the criteria set by recognized pharmacopeias.

Manufacturing Methods

A method for producing these compositions involves direct mixing of psilocybin with acceptable excipients, followed by encapsulation. This process is designed to ensure compliance with established content uniformity standards, facilitating effective treatment options for patients with depressive disorders.